Exploring ways to improve CDI outcomes;Comment améliorer le pronostic des infections à Clostridium difficile ?

Medecine et Maladies Infectieuses

Volumn 48, Issue 1, 2018, Pages 10-17

  Galperine T ^a   Guery, B ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antibiotics; Clostridium difficile; Fecal microbiota transplantation; Vaccine

Indexed keywords

ANTIINFECTIVE AGENT; CADAZOLID; FIDAXOMICIN; MDX 1388; METRONIDAZOLE; RIDINILAZOLE; RIFAXIMIN; SUROTOMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN; VLA 84; BACTERIAL VACCINE; RECOMBINANT VACCINE;

ANTIMICROBIAL ACTIVITY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; INTESTINE FLORA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CLOSTRIDIUM INFECTION; DRUG EFFECT; EXPERIMENTAL THERAPY; MICROBIOLOGY; PASSIVE IMMUNIZATION; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE;

ANTI-BACTERIAL AGENTS; BACTERIAL VACCINES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HUMANS; IMMUNIZATION, PASSIVE; RECURRENCE; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 85040327154     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2017.10.009     Document Type: Review

References (69)

1. Lessa, F.C., Mu, Y., Bamberg, W.M., et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 372 (2015), 825–834.
2. Hall, A.J., Curns, A.T., McDonald, L.C., Parashar, U.D., Lopman, B.A., The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis 55 (2012), 216–223.
3. Centers for Disease Control and Prevention, (CDC), Antibiotic resistance threats in the United States. 2013 https://www.cdc.gov/drugresistance/threat-report-2013/index.html.
4. Bolton, R.P., Culshaw, M.A., Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27 (1986), 1169–1172.
5. Zar, F.A., Bakkanagari, S.R., Moorthi KMLST, Davis, M.B., A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45 (2007), 302–307.
6. Johnson, S., Louie, T.J., Gerding, D.N., et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 59 (2014), 345–354.
7. Stevens, V.W., Nelson, R.E., Schwab-Daugherty, E.M., et al. Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with Clostridium difficile infection. JAMA Intern Med 177 (2017), 546–548.
8. Sullivan, K.M., Spooner, L.M., Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection. Ann Pharmacother 44 (2010), 352–359.
9. Louie, T.J., Miller, M.A., Mullane, K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364 (2011), 422–431.
10. Cornely, O.A., Crook, D.W., Esposito, R., et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12 (2012), 281–289.
11. Kelly, C.P., Can we identify patients at high-risk of recurrent Clostridium difficile infection?. Clin Microbiol Infect 18 (2012), 21–27.
12. Louie, T.J., Cannon, K., Byrne, B., et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 55 (2012), S132–S142.
13. Chilton, C.H., Crowther, G.S., Todhunter, S.L., et al. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model. J Antimicrob Chemother 70 (2015), 2598–2607.
14. Guery, B., Menichetti, F., Goldenberg, S., et al. Randomised, controlled, open-label study comparing the efficacy of extended-pulsed fidaxomicin (EPFX) with vancomycin therapy for sustained clinical cure of Clostridium difficile infection in an older population: the EXTEND study 27th ECCMID. 2017, Vienna.
15. McFarland, L.V., Elmer, G.W., Surawicz, C.M., Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97 (2002), 1769–1775.
16. Hota, S.S., Sales, V., Tomlinson, G., et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: an open-label, randomized controlled trial. Clin Infect Dis 64:3 (2017), 265–271 [ciw731].
17. Galperine, T., Sokol, H., Guery, B., Fecal microbiota transplantation: do we need harmonization?. Clin Infect Dis, 64, 2017, 1292.
18. Nelson, R.L., Suda, K.J., Evans, C.T., Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev, 3, 2017, CD004610.
19. Rashid, M.-U., Lozano, H.M., Weintraub, A., Nord, C.E., In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden. Anaerobe 20 (2013), 32–35.
20. Locher, H.H., Caspers, P., Bruyere, T., et al. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother 58 (2014), 901–908.
21. Locher, H.H., Seiler, P., Chen, X., et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother 58 (2014), 892–900.
22. Louie, T., Nord, C.E., Talbot, G.H., et al. Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrob Agents Chemother 59 (2015), 6266–6273.
23. Gerding, D.N., Hecht, D.W., Louie, T., et al. Susceptibility of Clostridium difficile isolates from a phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. J Antimicrob Chemother 71 (2015), 213–219.
24. Mascio, C.T.M., Mortin, L.I., Howland, K.T., et al. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob Agents Chemother 56 (2012), 5023–5030.
25. Reigadas, E., Alcalá, L., Marín, M., et al. In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain. J Antimicrob Chemother, 71(11), 2015, 3319.
26. Bouillaut, L., McBride, S., Sorg, J.A., et al. Effects of surotomycin on Clostridium difficile viability and toxin production in vitro. Antimicrob Agents Chemother 59 (2015), 4199–4205.
27. Endres, B.T., Bassères, E., Khaleduzzaman, M., Alam, M.J., Chesnel, L., Garey, K.W., Evaluating the effects of surotomycin treatment on Clostridium difficile toxin A and B production, immune response, and morphological changes. Antimicrob Agents Chemother 60 (2016), 3519–3523.
28. Lee, C.H., Patino, H., Stevens, C., et al. Surotomycin versus vancomycin for Clostridium difficile infection: phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial. J Antimicrob Chemother 71:10 (2016), 2964–2971 [dkw246–8].
29. Boix, V., Fedorak, R.N., Mullane, K.M., et al. Primary outcomes from a phase 3, randomized, double-blind, active-controlled trial of surotomycin in subjects with Clostridium difficile infection. Open Forum Infect Dis, 4(1), 2017, ofw275.
30. Vickers, R.J., Tillotson, G., Goldstein, E.J.C., Citron, D.M., Garey, K.W., Wilcox, M.H., Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents 48 (2016), 137–143.
31. Bassères, E., Endres, B.T., Khaleduzzaman, M., et al. Impact on toxin production and cell morphology in Clostridium difficileby ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother 71 (2016), 1245–1251.
32. Vickers, R.J., Tillotson, G.S., Nathan, R., et al. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infect Dis 17 (2017), 735–744.
33. Garey, K.W., Jiang, Z.-D., Bellard, A., DuPont, H.L., Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol 43 (2009), 91–93.
34. Garey, K.W., Ghantoji, S.S., Shah, D.N., et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 66 (2011), 2850–2855.
35. Seal, D., Borriello, S.P., Barclay, F., Welch, A., Piper, M., Bonnycastle, M., Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol 6 (1987), 51–53.
36. Villano, S.A., Seiberling, M., Tatarowicz, W., Monnot-Chase, E., Gerding, D.N., Evaluation of an oral suspension of VP20621, spores of non-toxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother 56 (2012), 5224–5229.
37. Gerding, D.N., Meyer, T., Lee, C., et al. Administration of spores of non-toxigenic Clostridium difficile strain M3 for prevention of recurrent C difficile infection. JAMA 313:17 (2015), 1719–1727.
38. Eiseman, B., Silen, W., Bascom, G.S., Kauvar, A.J., Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44 (1958), 854–859.
39. Chang, J.Y., Antonopoulos, D.A., Kalra, A., et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile–associated diarrhea. J Infect Dis 197 (2008), 435–438.
40. van Nood, E., Vrieze, A., Nieuwdorp, M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368 (2013), 407–415.
41. Cammarota, G., Masucci, L., Ianiro, G., et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 41 (2015), 835–843.
42. Seekatz, A.M., Aas, J., Gessert, C.E., et al. Recovery of the gut microbiome following fecal microbiota transplantation. mBio, 5, 2014, e00893-14.
43. Debast, S.B., Bauer, M.P., Kuijper, E.J., Committee. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Paul M, ed. Clin Microbiol Infect 20:Suppl. 2 (2014), 1–26.
44. Cammarota, G., Ianiro, G., Magalini, S., Gasbarrini, A., Gui, D., Decrease in surgery for Clostridium difficile infection after starting a program to transplant fecal microbiota. Ann Intern Med 163 (2015), 487–488.
45. Kelly, C.R., Khoruts, A., Staley, C., et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med 165 (2016), 609–616.
46. Agrawal, M., Aroniadis, O.C., Brandt, L.J., et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol 50 (2016), 403–407.
47. Girotra, M., Garg, S., Anand, R., Song, Y., Dutta, S.K., Fecal microbiota transplantation for recurrent Clostridium difficile infection in the elderly: long-term outcomes and microbiota changes. Dig Dis Sci 61:10 (2016), 3007–3015.
48. Wang, S., Xu, M., Wang, W., et al. Systematic review: adverse events of fecal microbiota transplantation. PLoS ONE, 11(8), 2016, e0161174.
49. Sokol, H., Galperine, T., Kapel, N., et al. Faecal microbiota transplantation in recurrent Clostridium difficile infection: recommendations from the French Group of Faecal microbiota Transplantation. Dig Liver Dis 48 (2016), 242–247.
50. Paramsothy, S., Borody, T.J., Lin, E., et al. Donor recruitment for fecal microbiota transplantation. Inflamm Bowel Dis 21 (2015), 1600–1606.
51. Lee, C.H., Steiner, T., Petrof, E.O., et al. Frozen vs. fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection. JAMA 315 (2016), 142–148.
52. Youngster, I., Russell, G.H., Pindar, C., Ziv-Baran, T., Sauk, J., Hohmann, E.L., Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312 (2014), 1772–1777.
53. Youngster, I., Mahabamunuge, J., Systrom, H.K., et al. Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med, 2016, 1–4.
54. Lawley, T.D., Clare, S., Walker, A.W., et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog, 8, 2012, e1002995.
55. Petrof, E.O., Gloor, G.B., Vanner, S.J., et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome, 1, 2013, 3.
56. Orenstein, R., Dubberke, E., Hardi, R., et al. Safety and durability of RBX2660 (Microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study. Clin Infect Dis 62 (2016), 596–602.
57. Hirsch, B.E., Saraiya, N., Poeth, K., Schwartz, R.M., Epstein, M.E., Honig, G., Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect Dis, 2015, 1–9.
58. Khanna, S., Pardi, D.S., Kelly, C.R., et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis 214 (2016), 173–181.
59. Kyne, L., Warny, M., Qamar, A., Kelly, C.P., Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342 (2000), 390–397.
60. Kyne, L., Warny, M., Qamar, A., Kelly, C.P., Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357 (2001), 189–193.
61. van Dissel, J.T., de Groot, N., Hensgens, C.M., et al. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 54 (2005), 197–205.
62. Babcock, G.J., Broering, T.J., Hernandez, H.J., et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74 (2006), 6339–6347.
63. Lowy, I., Molrine, D.C., Leav, B.A., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362 (2010), 197–205.
64. Wilcox, M.H., Gerding, D.N., Poxton, I.R., et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 376 (2017), 305–317.
65. Steele, J., Mukherjee, J., Parry, N., Tzipori, S., Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis 207 (2013), 323–330.
66. Yang, Z., Ramsey, J., Hamza, T., et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab Young VB, ed. Infect Immun 83 (2015), 822–831.
67. Hussack, G., Tanha, J., An update on antibody-based immunotherapies for Clostridium difficile infection. Clin Exp Gastroenterol 9 (2016), 209–224.
68. Salnikova, M.S., Joshi, S.B., Rytting, J.H., Warny, M., Middaugh, C.R., Preformulation studies of Clostridium difficile toxoids A and B. J Pharm Sci 97 (2008), 4194–4207.
69. Sougioultzis, S., Kyne, L., Drudy, D., et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. YGAST 128 (2005), 764–770.